Literature DB >> 8594637

Vancomycin levels after intravitreal injection. Effects of inflammation and surgery.

H E Aguilar1, T A Meredith, A el-Massry, A Shaarawy, M Kincaid, J Dick, D J Ritchie, R M Reichley, M K Neisman.   

Abstract

OBJECTIVE: Vancomycin hydrochloride for intraocular injection is the drug of choice for the treatment of suspected gram-positive endophthalmitis. To study its intraocular pharmacokinetics, we injected vancomycin into the vitreous cavity of phakic, aphakic, and aphakic-vitrectomized rabbit eyes and determined its rate of clearance. Inflamed eyes were compared to control eyes in each group.
METHODS: Three groups of eyes were prepared. The eyes in Group 1 were phakic, the eyes in Group 2 had the lens removed, and the eyes in Group 3 had both the lens and central vitreous removed. Each group was subdivided into a control group and a group made inflamed by injection of heat-killed Staphylococcus epidermidis. Vancomycin hydrochloride 1 mg in 0.1 cc of diluent was injected into the midvitreous cavity and samples obtained at 2 or 3, 8, 24, and 48 hours after injection. Vancomycin concentrations were measured and clearance rates were calculated for each of the groups.
RESULTS: Vancomycin was cleared substantially faster from aphakic-vitrectomized eyes (half-life 9.0 hours) and aphakic eyes (half-life 8.9 hours) than phakic eyes (half-life 25.1 hours). Inflammation increased the rate of elimination of vancomycin only in the aphakic group.
CONCLUSIONS: Clearance of vancomycin from the phakic eye is prolonged compared to that of beta-lactam antibiotics, an important pharmacokinetic advantage in treating endophthalmitis. Its clearance from aphakic-vitrectomized eyes is dramatically faster than from phakic eyes and is similar to that of other antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8594637

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  15 in total

1.  Temporal pattern of resolution/recurrence of choroidal neovascularization during bevacizumab therapy for wet age-related macular degeneration.

Authors:  Haiyan Wang; Giulio Barteselli; William R Freeman; Su Na Lee; Jay Chhablani; Sharif El-Emam; Lingyun Cheng
Journal:  Int J Ophthalmol       Date:  2013-10-18       Impact factor: 1.779

2.  Persistently Vitreous Culture-Positive Exogenous Bacterial Endophthalmitis.

Authors:  Ella H Leung; Ajay E Kuriyan; Harry W Flynn; Darlene Miller; Laura C Huang
Journal:  Am J Ophthalmol       Date:  2016-02-26       Impact factor: 5.258

3.  Retinal toxicity after intracameral use of a standard dose of cefuroxime during cataract surgery.

Authors:  Céline Faure; Daniel Perreira; Isabelle Audo
Journal:  Doc Ophthalmol       Date:  2014-10-16       Impact factor: 2.379

4.  Serum levels of intravitreal bevacizumab after vitrectomy, lensectomy and non-surgical controls.

Authors:  John B Christoforidis; Zhiliang Xie; Angela Jiang; Jillian Wang; Cedric Pratt; Anne Gemensky-Metzler; Mahmoud Abdel-Rasoul; Sashwati Roy; Zhongfa Liu
Journal:  Curr Eye Res       Date:  2013-04-02       Impact factor: 2.424

5.  Intravitreal vancomycin and gentamicin concentrations in patients with postoperative endophthalmitis.

Authors:  I M Gan; J T van Dissel; W H Beekhuis; W Swart; J C van Meurs
Journal:  Br J Ophthalmol       Date:  2001-11       Impact factor: 4.638

Review 6.  Antimicrobial guide to posterior segment infections.

Authors:  Tapan P Patel; David N Zacks; Vaidehi S Dedania
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-11-06       Impact factor: 3.117

7.  Anatomic and pharmacokinetic properties of intravitreal bevacizumab and ranibizumab after vitrectomy and lensectomy.

Authors:  John B Christoforidis; Michelle M Williams; Jillian Wang; Angela Jiang; Cedric Pratt; Mahmoud Abdel-Rasoul; George H Hinkle; Michael V Knopp
Journal:  Retina       Date:  2013-05       Impact factor: 4.256

8.  Intravitreal vancomycin and amikacin versus intravenous imipenem in the treatment of experimental Staphylococcus aureus endophthalmitis.

Authors:  Michael Engelbert; Herminia Miño de Kaspar; Martin Thiel; Thomas Grasbon; Christopher N Ta; Markus Schulze-Schwering; Volker Klauss; Anselm Kampik
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-02-24       Impact factor: 3.117

9.  Management of endophthalmitis while preserving the uninvolved crystalline lens.

Authors:  Justin Townsend; Avinash Pathengay; Harry W Flynn; Darlene Miller
Journal:  Clin Ophthalmol       Date:  2012-03-20

10.  Intracameral cefuroxime in combined pars plana vitrectomy and phacoemulsification: a study of safety.

Authors:  Gianluca Besozzi; Attilio Di Salvatore; Daniele Cardillo; Alessandro Finzi; Joseph Sajish Pinackatt; Andrea Baldi; Alessandro Monfardini; Valeria Forioli; Rino Frisina; Barbara Parolini
Journal:  Clin Ophthalmol       Date:  2018-08-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.